Latest Listings And Ipos News

Recce Pharmaceuticals secured a non-binding term sheet with a major Middle Eastern pharma for its diabetic foot infection treatment and raised A$4 million to fund pivotal Phase 3 trials in Australia and Indonesia.

Flagship Minerals has received full payment of US$4 million for its RK Lithium Project sale, advancing its strategic pivot towards gold and copper assets in Chile and Canada.

Patagonia Lithium has reached 200 metres depth at Cilon Well 8, reporting strong brine flow rates and specific gravity readings indicative of lithium presence, while confirming no environmental impact from drilling activities.

Koonenberry Gold Limited has locked in $4 million through a share placement to accelerate drilling and geochemical studies across its NSW projects, including the newly acquired Gundagai.

Noumi Limited has struck a binding deal with major shareholder Arrovest to acquire all remaining shares via a scheme of arrangement, offering shareholders a 12.2% premium amid looming $610 million convertible note maturity.

ClearVue Technologies has exceeded its $1 million target in a Share Purchase Plan, raising $1.29 million and issuing over 14.6 million shares with free attaching options pending shareholder approval.

PC Gold has significantly expanded its Spring Hill gold resource to 1.51 million ounces, unveiling a new high-grade Link Zone that could underpin a long-life mining operation in the Northern Territory.

Unith Ltd (ASX:UNT) is raising up to $1.75 million through a non-renounceable entitlement offer priced at 0.8 cents per share, accompanied by free-attaching listed options, aiming to accelerate technology and commercial development.

Valiant Gold has successfully re-entered the Comet Underground Mine, uncovering better-than-expected conditions that could accelerate the mine's restart timeline. The company is progressing engineering and site works targeting 304,000 ounces from its 3.77Mt resource.

Telix Pharmaceuticals reported a 21% year-on-year revenue jump to US$247 million in Q2 2026, buoyed by strong Precision Medicine sales and a new Regeneron partnership. The company also secured FDA alignment on a pivotal prostate cancer trial and expanded its manufacturing footprint.

Waypoint REIT's half-year valuation shows a small 0.4% lift in portfolio value and a 0.7% increase in net tangible assets per security to $2.92, with capitalisation rates softening slightly.

Podium Minerals has confirmed robust platinum group metals mineralisation extending to 500 metres depth at Parks Reef, reinforcing the project's scale and growth potential amid supportive market fundamentals.